36-38-Nath Bio-Genes-Aventis Pharma India-Dr Reddy's Laboratories
15 June 2010 | News
36
Nath Bio-Genes
Nath Bio-Genes, a hybrid seed producing and biotechnology company clocked an annual revenue of Rs 85 crore in 2009-2010. In addition to direct sales, it has sub-licensed the technology to other companies. The sub-licensees includes companies such as Unipho Seeds and Biogenetics, Zuari Seeds, Navkar Seeds, Sri Rama Agri-Genetics, and Daftari Agro. Nath Bio-Genes, independently as well as jointly with its sister organization Global Trangenes, have forged R&D linkages with several renowned institutions in the world.
The company undertakes seed production in over 30,000 acres of land with about 25,000 farmers in the states of Andhra Pradesh (AP), Gujarat, Karnataka, Maharashtra, Rajasthan and Tamilnadu. The company has elaborate seed processing facilities at Aurangabad, Coimbatore, Medchel (AP) and Munipally (AP) for ginning, delinting, processing, treating, packing and storage of seeds.
37
Aventis Pharma India
Aventis Pharma clocked a total sales of Rs 68.34 crore in 2009-2010. In February 2009, there was a discontinuance of distribution of the anti rabies vaccine, Rabipur which led to a slight drop in its total revenues. During the fiscal, its insulin brand, Lantus had a sales growth of 38.6 percent. It presently has a market share of 8.7 percent in this segment. It has become the third largest insulin brand in the last quarter of 2009. Aventis has state-of-the-art manufacturing sites at Goa and Ankleshwar, where a number of pharmaceutical ingredients and formulations are produced. Both the sites comply with prevailing Good Manufacturing Practice (GMP) and Health, Safety and Environment (HSE) standards and score highly in terms of performance. The Ankleshwar plant achieved a record production of four billion tablets. New products were manufactured and launched in the domestic Tier 2 markets. The upgradation of the laboratory at Ankleshwar was completed and it was made operational. The company has 2106 employees as on December 31, 2009.
38
Dr Reddy’s Laboratories
The total biotech revenue of Dr Reddy’s has grown to Rs 62.5 crore in FY 2009-10 from Rs 40 crore in FY 2008-09. The company sells two biologic products—Grafeel (generic Filgrastim) and Reditux, (generic Rituximab), another eight products are in the pipeline. As a fully integrated pharmaceutical company, it runs three core businesses - pharmaceutical services and active ingredients, generics, and proprietary products, which includes new chemical entities (NCEs), differentiated formulations, and generic biopharmaceuticals. Dr Reddy’s conducts NCE research in the areas of metabolic disorders, cardiovascular indications, anti-infectives and inflammation. The company’s products are marketed globally, with a focus on India, US, Europe and Russia. It has eight FDA-inspected plants and three technology centers.
Nath Bio-Genes
| MD | Nandkishor Kagliwal |
 |
| Business | Engaged in research, processing and producing hybrid
seeds including Bt seeds |
|
| Start-up Year | 1981 | |
| Biotech Revenue | Rs 85 crore | |
| Address | Nath House, Nath Road, Aurangabad - 431 005 |
|
| Tel | +91-240-2376314 | |
| Fax | +91-240-2376188 |
|
| Website | www.nathseeds.com |
Nath Bio-Genes, a hybrid seed producing and biotechnology company clocked an annual revenue of Rs 85 crore in 2009-2010. In addition to direct sales, it has sub-licensed the technology to other companies. The sub-licensees includes companies such as Unipho Seeds and Biogenetics, Zuari Seeds, Navkar Seeds, Sri Rama Agri-Genetics, and Daftari Agro. Nath Bio-Genes, independently as well as jointly with its sister organization Global Trangenes, have forged R&D linkages with several renowned institutions in the world.
The company undertakes seed production in over 30,000 acres of land with about 25,000 farmers in the states of Andhra Pradesh (AP), Gujarat, Karnataka, Maharashtra, Rajasthan and Tamilnadu. The company has elaborate seed processing facilities at Aurangabad, Coimbatore, Medchel (AP) and Munipally (AP) for ginning, delinting, processing, treating, packing and storage of seeds.
37
Aventis Pharma India
| CEO | Dr Shailesh Ayyangar |
 |
| Business | Manufacturing and marketing of pharma products |
|
| Start-up Year | - | |
| Biotech Revenue | Rs 68.34 crore |
|
| Address | Aventis House, 54/A, Sir Mathuradas, Vasanji
Road, Andheri East, Mumbai-400093 |
|
| Tel | +91-22-28278000 | |
| Fax | +91-22-28370939 | |
| Website | www.aventispharmaindia.com |
Aventis Pharma clocked a total sales of Rs 68.34 crore in 2009-2010. In February 2009, there was a discontinuance of distribution of the anti rabies vaccine, Rabipur which led to a slight drop in its total revenues. During the fiscal, its insulin brand, Lantus had a sales growth of 38.6 percent. It presently has a market share of 8.7 percent in this segment. It has become the third largest insulin brand in the last quarter of 2009. Aventis has state-of-the-art manufacturing sites at Goa and Ankleshwar, where a number of pharmaceutical ingredients and formulations are produced. Both the sites comply with prevailing Good Manufacturing Practice (GMP) and Health, Safety and Environment (HSE) standards and score highly in terms of performance. The Ankleshwar plant achieved a record production of four billion tablets. New products were manufactured and launched in the domestic Tier 2 markets. The upgradation of the laboratory at Ankleshwar was completed and it was made operational. The company has 2106 employees as on December 31, 2009.
38
Dr Reddy’s Laboratories
| CEO | GV Prasad |  |
| Business | Biopharmaceuticals |
|
| Start-up Year | 1984 | |
| Biotech Revenue | Rs 62.5 crore |
|
| Address | 7-1-27, Ameerpet, Hyderabad – 500 016 |
|
| Tel | +91-40-23731946 | |
| Fax | +91-40-23731955 | |
| Website | www.drreddys.com |
The total biotech revenue of Dr Reddy’s has grown to Rs 62.5 crore in FY 2009-10 from Rs 40 crore in FY 2008-09. The company sells two biologic products—Grafeel (generic Filgrastim) and Reditux, (generic Rituximab), another eight products are in the pipeline. As a fully integrated pharmaceutical company, it runs three core businesses - pharmaceutical services and active ingredients, generics, and proprietary products, which includes new chemical entities (NCEs), differentiated formulations, and generic biopharmaceuticals. Dr Reddy’s conducts NCE research in the areas of metabolic disorders, cardiovascular indications, anti-infectives and inflammation. The company’s products are marketed globally, with a focus on India, US, Europe and Russia. It has eight FDA-inspected plants and three technology centers.
